<DOC>
	<DOCNO>NCT01026454</DOCNO>
	<brief_summary>The purpose study determine whether treat HSV-2 either valacyclovir acyclovir effective suppress HIV-1 virus level people co-infected HIV-1 HSV-2 .</brief_summary>
	<brief_title>Valacyclovir vs. Acyclovir HSV-2 Suppressive Therapy : Effect Plasma HIV-1 Levels Among HIV-1/HSV-2 Co-infected Persons</brief_title>
	<detailed_description>Sexual transmission responsible vast majority HIV-1 infection among adult worldwide . In sub-Saharan Africa , region hard hit HIV-1 epidemic , HSV-2 prevalence 30-50 % see general population prevalence 90 % infected HIV-1 . HSV-2 common , risk , HIV-1 infection , HSV-2 reactivation increase HIV-1 acquisition infectiousness . Recent study show suppression HSV-2 sustain effect lower HIV-1 level blood plasma . New data raise question whether high dos HSV-2 suppressive therapy might effective suppress HIV-1 level . Acyclovir valacyclovir , choose use study , safe effective treatment decrease frequency HSV-2 reactivation shed . The standard dose acyclovir 400 mg twice day . Valacyclovir , drug convert acyclovir absorption , deliver high concentration acyclovir . 1.5 gram valacyclovir , use provide high dose acyclovir , compare standard dose 400 mg twice day acyclovir .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<criteria>HIV1 seropositive Not HIV1 antiretroviral therapy planning initiate antiretroviral therapy study period CD4 cell count &gt; 250 cell/ÂµL Not otherwise eligible antiretroviral therapy accord Uganda national guideline Detectable HIV1 plasma viral load HSV2 seropositive Not intend move area duration study participation . Able participate study Partners Prevention site Thika , Kenya Known history adverse reaction acyclovir , valacyclovir , famciclovir . Planned use acyclovir , valacyclovir , famciclovir Use ganciclovir , foscarnet , cidofovir Known medical history seizure Serum creatinine &gt; 1.5 mg/dL AST ALT &gt; 3 time upper limit normal Hematocrit &lt; 30 % Absolute neutrophil count &lt; 1000 Platelet count &lt; 75,000 History thrombotic microangiopathy Any condition , opinion principal investigator , may compromise ability follow study procedure complete study Participation another HIV therapeutic trial For woman , pregnancy confirm urine pregnancy test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>HSV</keyword>
	<keyword>HIV</keyword>
</DOC>